Friday, July 14, 2023
InnoCare Pharma and ArriVent Biopharma have entered into a clinical development collaboration to assess the combination of two investigational drugs, ICP-189 and furmonertinib, for the treatment of advanced non-small cell lung cancer (NSCLC).
Under the agreement, InnoCare and ArriVent will jointly conduct a clinical study to evaluate the efficacy and safety of combining ICP-189 with furmonertinib in patients with advanced NSCLC.
ICP-189 is an oral allosteric inhibitor of SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase), a protein involved in cell signalling pathways. It is developed as a potential treatment for solid tumours, either as a standalone therapy or in combination with other anti-tumour agents. Early studies of ICP-189 have shown promising pharmacokinetics (PK), a long half-life, and favourable safety and tolerability.
This collaboration represents an opportunity for ArriVent to expand its furmonertinib clinical development programme beyond monotherapy and explore the potential benefits of combination therapy in this setting. If the clinical trials are successful and the combination therapy is approved, the combination of furmonertinib with SHP2 inhibitors like ICP-189 will provide an additional treatment option for patients with advanced or metastatic lung cancer.
